Vivek Subbiah: F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow! It’s Big news on Friday. F.D.A. Grants Early Access to Promising Drug for […]
AI Summary: The FDA has authorized early access to a promising experimental therapy for pancreatic cancer, opening an expanded‑access pathway so eligible patients can receive the drug before full approval. Regulators based the decision on encouraging early clinical signals of activity and manageable safety data, aiming to offer options for a disease with few effective treatments—because pancreatic cancer isn’t known for its patience.
- Daraxonrasib expanded access: FDA opens early pathway (6)
- Research advances: diagnostics and targeted therapies for pancreatic cancer (5)
- All Other Stories
Daraxonrasib expanded access: FDA opens early pathway
Research advances: diagnostics and targeted therapies for pancreatic cancer
All Other Stories
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
Kyle LaHucik / endpoints - Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ...
AI Summary: Chiesi Group agreed to buy KalVista for $1.9 billion to secure an approved therapy and expand its rare-disease footprint. The deal transfers marketed assets and R&D capacity, positioning Chiesi to scale rare-disease revenues and invest in next-wave therapeutics — essentially a big check for a bigger strategic play.
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials
Frank Vinluan / medcitynews - Avalayn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027. The post Avalyn Pharma Takes a Breath to…
AI Summary: Avalyn Pharma has substantially increased its IPO, targeting roughly $300 million to bankroll late-stage trials of its respiratory drug candidate. The move reflects strong investor enthusiasm for lung‑disease therapeutics and gives the company a bigger war chest to advance programs previously dependent on venture capital and partnerships.
Matthew Kurian: ODAC Votes 6–3 Against Camizestrant Approval In SERENA-6
oncodaily - Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn: “Breaking: ODAC Votes 6-3 Against Camizestrant Approval […]
AI Summary: An FDA oncology advisory committee delivered a 6–3 vote against approval of camizestrant following review of the SERENA‑6 trial, flagging concerns about the data package and the drug’s claimed “new paradigm.” The panel’s negative recommendation raises serious regulatory and commercial uncertainty for AstraZeneca’s oral SERD program and its path forward.
- Implications for HR+/HER2- treatment landscape (3)
- ODAC rejects camizestrant approval (8)
- All Other Stories
Implications for HR+/HER2- treatment landscape
ODAC rejects camizestrant approval
All Other Stories
FDA Announced Two Major Milestones in Implementing Real-Time Clinical Trials
oncodaily - U.S. Food and Drug Administration (FDA) shared a post on LinkedIn: “Today, the FDA announced two major milestones in implementing real-time clinical trials: Successful Proofs-of-Concept: FDA unveiled proof-of-concept trials with […]
AI Summary: The FDA announced major steps to implement real‑time clinical trial review through a new research collaboration, aiming to accelerate data flow and regulatory oversight. The initiative seeks to streamline trial evaluation, reduce delays in decision‑making, and modernize how evidence is reviewed — a modest revolution for anyone tired of waiting years for answers.
- AI, data and digital tools modernizing clinical trials (3)
- Equity, ethics and patient access in clinical trials (4)
- FDA real-time trial launches with academic and industry partners (4)
- All Other Stories
AI, data and digital tools modernizing clinical trials
Equity, ethics and patient access in clinical trials
FDA real-time trial launches with academic and industry partners
All Other Stories
Preeclampsia could be treated with 'blood filtering' therapy, early study hints
livescience - A blood-filtering therapy for preeclampsia is safe for pregnant patients and their babies, according to a new pilot study.
AI Summary: Early clinical work suggests removing a circulating anti‑angiogenic factor can safely extend pregnancies in severe preeclampsia. Researchers used targeted extracorporeal filtration to lower soluble Fms‑like tyrosine kinase‑1 (sFlt‑1) levels, improving maternal and fetal stability long enough to delay delivery and reduce immediate risks, meriting larger controlled trials.
Erectile disorder: How science is moving beyond Viagra
medicalxpress - Erectile disorder (ED) refers to a persistent difficulty achieving or maintaining an erection sufficient for satisfying sexual activity. It affects millions of men worldwide, including up to 1 in 4 in the United States. Beyond physical functioning, erecti…
AI Summary: Researchers are advancing alternatives to sildenafil-era approaches for erectile disorder, exploring new biological targets and therapies that aim to restore function rather than just patch symptoms. The coverage explains emerging mechanisms, investigational treatments and the shifting clinical landscape—because sometimes a Band-Aid on performance isn’t the long-term plan.
Eugene Braunwald, Whose Research Reshaped Cardiology, Dies at 96
Jonathan Kandell / nytimes - His work changed how doctors understood heart attacks, heart failure and coronary artery disease, and helped lead to therapies that saved millions of lives.
AI Summary: Eugene Braunwald, a towering figure whose research reshaped modern cardiology, has died at 96. Colleagues remember his seminal contributions to cardiac physiology, therapeutics, and clinical practice that set the stage for decades of advances. His passing marks the end of an era for a field he helped steer.
Introducing the Chairs at ISCO Congress 2026 – Part 1
oncodaily - International School of Clinical Oncology – ISCO shared a series of posts on Facebook, introducing the Chairs at the upcoming ISCO Congress 2026: 1. “We are delighted to welcome Prof. […]
AI Summary: The ISCO Congress 2026 has unveiled its chairpersons and session lineup, spotlighting leaders shaping the program and key scientific themes. Organizers framed the event as a platform for multidisciplinary exchange and translational oncology priorities, aiming to accelerate research-to-clinic progress while giving attendees plenty to talk about between coffee breaks.
- Leadership, training and career-development programs (4)
- Major trial takeaways across 2026 oncology congresses (4)
- Meet the ISCO 2026 Chairs and Honorees (6)
- Scientific tracks: AI, translational & cellular therapy (4)
- All Other Stories
Leadership, training and career-development programs
Major trial takeaways across 2026 oncology congresses
Meet the ISCO 2026 Chairs and Honorees
Scientific tracks: AI, translational & cellular therapy
All Other Stories
WHO approves first malaria treatment for infants
medicalxpress - The World Health Organization announced Friday that it had given prequalification approval to a malaria treatment for newborns and infants for the first time.
AI Summary: The World Health Organization has cleared the first malaria treatment specifically for infants, granting prequalification that paves the way for broader procurement and use in endemic countries. Regulators' sign-off targets a vulnerable age group long underserved by effective pediatric therapies, potentially speeding distribution through global health channels and donor programs.
A deep learning pathomics platform may help predict response to immunotherapy in lung cancer patients
medicalxpress - A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American A…
AI Summary: Researchers developed a deep‑learning pathomics platform that analyzes routine histology to predict which lung cancer patients are likely to respond to immunotherapy. By extracting subtle morphological patterns invisible to the human eye, the tool promises to refine treatment selection and spare nonresponders unnecessary toxicity—assuming clinicians trust an algorithm more than their gut.
- AI pathomics flags immunotherapy responders in lung cancer (4)
- Challenges deploying AI in lung cancer diagnosis and care (3)
- Evolving lung cancer immunotherapy trials and biomarker debates (4)
- All Other Stories
AI pathomics flags immunotherapy responders in lung cancer
Challenges deploying AI in lung cancer diagnosis and care
Evolving lung cancer immunotherapy trials and biomarker debates
All Other Stories
Distribution of Phase I lung cancer trials may be consolidating at top-performing US sites
medicalxpress - Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest-volume clinical trial si…
AI Summary: A new analysis shows Phase I lung cancer trials are becoming concentrated at a relatively small number of leading U.S. centers, raising concerns about geographic inequity in access to early‑phase studies. The trend could speed drug development at elite sites while leaving patients in other regions with fewer experimental options and longer travel burdens.
- Conference highlights, care models and awareness (4)
- Consolidation at top U.S. Phase I centers (3)
- Early-phase trials and next-gen therapies (4)
- All Other Stories
Conference highlights, care models and awareness
Consolidation at top U.S. Phase I centers
Early-phase trials and next-gen therapies
All Other Stories
FDA backs 3 psychedelic drug studies for mental illness
Ella Ruder / beckershospitalreview - The FDA is issuing national priority vouchers to three companies studying psychedelic drugs to treat serious mental illness. The vouchers were issued to companies studying psilocybin for treatment-resistant depression and major depressive disorder as well…
AI Summary: The FDA announced a targeted push to accelerate clinical research into psychedelics for mental illness, issuing three commissioner vouchers to support rigorous trials of psychedelic therapies. The move aims to fast-track evidence generation under regulatory oversight, signalling growing agency willingness to explore unconventional treatments while keeping safety and trial standards squarely in view.
- FDA voucher push and federal policy shift (5)
- Psilocybin and brain science (4)
- Real-world use, safety and clinical readiness (3)
- All Other Stories
FDA voucher push and federal policy shift
Psilocybin and brain science
Real-world use, safety and clinical readiness
All Other Stories
CMS, FDA announce new program to speed up Medicare coverage of breakthrough medical devices
fiercehealthcare - The Trump administration unveiled a new program to speed up Medicare coverage for breakthrough devices, touting that the new pathway cuts red tape for medical device companies to gain reimbursement. CMS said it will pause the existing TCET pathway.
AI Summary: CMS and the Food and Drug Administration launched a coordinated program to accelerate Medicare coverage for breakthrough medical devices, aiming to shorten the gap between regulatory approval and patient access. The initiative aligns agency review processes, defines eligibility, and seeks faster coverage decisions while maintaining safety and evidentiary standards.
- New imaging and monitoring devices promise faster, remote patient care. (3)
- On scene: agencies align to speed device approvals and coverage. (6)
New imaging and monitoring devices promise faster, remote patient care.
On scene: agencies align to speed device approvals and coverage.
Gene therapy improves hearing in 90% of patients with inherited deafness in largest trial of its kind
livescience - A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called OTOF.
AI Summary: A gene therapy for inherited deafness delivered dramatic results, restoring hearing in roughly 90% of treated patients in the largest trial of its kind. Investigators report durable improvements over follow-up, signaling a potential one-time intervention for certain genetic deafness types and challenging the notion that auditory loss is always irreversible. Hope, meet hard data.
- FDA approves first-ever gene therapy for inherited hearing loss (6)
- Primate study finds human-like genetic cause of blindness (1)
- Trial shows durable hearing restored in most patients (3)
FDA approves first-ever gene therapy for inherited hearing loss
Primate study finds human-like genetic cause of blindness
Trial shows durable hearing restored in most patients
FDA approves 1st 2-drug HIV treatment
Ella Jeffries / beckershospitalreview - The FDA has approved Merck’s once-daily, two-drug regimen for adults with virologically suppressed HIV-1. The treatment combines 100 mg doravirine and 0.25 mg islatravir and is indicated for patients with no history of virologic treatment failure and no k…
AI Summary: The FDA has approved Merck’s once‑daily two‑drug antiretroviral regimen, marking a notable market entrant poised to compete with established single‑pill therapies. Regulators cleared the novel combination on efficacy and safety data, setting up potential shifts in prescribing, pricing and competition — and giving Gilead something new to grumble about.
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial
Kristin Jensen / healthcaredive - A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.
AI Summary: Moderna has initiated a clinical trial of an mRNA vaccine targeting a potentially pandemic bird‑flu strain, joining global efforts to have a rapid‑response countermeasure ready. Regulators and public‑health experts hail the move as sensible pre‑emptive science—because nothing says “we planned for this” like testing the vaccine before the outbreak arrives.
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Omar Nadeem / nature - Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04365-yAs presented at the 2026 AACR Annual Meeting, in a phase 2 trial, treatment of patients with high-risk smoldering multiple myeloma with BCMA-targeting CAR T cell therapy cilta…
AI Summary: The CAR-PRISM phase 2 study reports that ciltacabtagene autoleucel, a BCMA-directed CAR T therapy, produced meaningful responses in patients with high‑risk smoldering multiple myeloma, suggesting potential to delay progression to symptomatic disease and defer immediate treatment. Early results show promising efficacy with manageable toxicities, hinting at a shift toward treating disease earlier rather than later.
- CAR-PRISM results: compelling MRD negativity, potential treatment shift (4)
- Experts weigh in: praise, safety concerns, and clinical enthusiasm (4)
- Policy and IO context: regulation, immune engineering, industry implications (3)
- All Other Stories
CAR-PRISM results: compelling MRD negativity, potential treatment shift
Experts weigh in: praise, safety concerns, and clinical enthusiasm
Policy and IO context: regulation, immune engineering, industry implications
All Other Stories
Long-term Use of Immunotherapy May Be Safe for Patients With Alveolar Soft Part Sarcoma
Kathleen Medora / aacr - SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from …
AI Summary: Observational data indicate extended checkpoint inhibitor therapy can be tolerated by patients with alveolar soft part sarcoma and may provide sustained disease control for many. The findings support considering prolonged treatment in select cases, while underscoring the need for vigilant monitoring for late toxicities and randomized trials to confirm benefit.
Improving oral care more than halves hospital-acquired pneumonia risk, major trial finds
medicalxpress - A landmark trial presented at ESCMID Global 2026 shows that improving oral hygiene for hospital patients can reduce the risk of non-ventilator-associated hospital-acquired pneumonia (NV-HAP) by 60%.
AI Summary: A major randomized trial found that simple improvements in oral care—regular toothbrushing and mouth hygiene—cut hospital‑acquired pneumonia risk by over half in hospitalized patients. The low‑cost intervention reduced respiratory complications and antibiotic use, suggesting wards could prevent serious infections with a toothbrush rather than another headline‑seeking drug.